磷酸西格列汀治疗2型糖尿病合并心血管高风险患者的临床疗效与安全性观察研究

Clinical Efficacy and Safety of Ceglitine Phosphate in the Treatment of Type 2 Diabetes Mellitus with High Risk of Cardiovascular Disease

目的分析磷酸西格列汀治疗2型糖尿病合并心血管高风险患者的临床疗效与安全性。方法将湖北省武汉市红十字会医院收治的80例2型糖尿病合并心血管高风险患者纳入本次试验,所选病例均来自2017年1月—2018年7月,按照随机双盲法进行分为治疗组与对照组,各40例。两组患者均采取常规降糖方案治疗,在此基础上对照组加用甘精胰岛素治疗,治疗组加用磷酸西格列汀治疗,就其临床疗效和安全性进行比较。结果治疗组患者空腹血糖、餐后2 h血糖、糖化血红蛋白水平、空腹胰岛素、胰岛素抵抗指数、体质量指数、TC、TG、LDL-C均明显低于对照组,HDL-C明显高于对照组,两组比较差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论磷酸西格列汀在治疗2型糖尿病合并心血管高风险患者中具有确切疗效,可有效改善其血糖、血脂水平,且用药安全性较高,值得在临床中推广应用。

Objective To analyze the clinical efficacy and safety of ceglitine phosphate in the treatment of type 2 diabetes mellitus with high risk of cardiovascular disease.Methods 80 patients with type 2 diabetes mellitus complicated with high risk cardiovascular disease were enrolled in this trial.The selected cases were from January 2017 to July 2018.They were divided into two groups according to the randomized double blind method:40 cases in the treatment group and 40 cases in the control group.The patients in both groups were treated with routine hypoglycemic regimen.On this basis,the patients in the control group were treated with insulin glargine and the patients in the treatment group were treated with ceglitine phosphate.The clinical efficacy and safety of the two groups were compared.Results the patients in the treatment group were fasting.Blood glucose,2 hours postprandial blood glucose,glycosylated hemoglobin level,fasting insulin,insulin resistance index,body mass index,TC,TG,LDL-C were significantly lower than those in the control group,while HDL-C was significantly higher than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Ceglitine phosphate has a definite curative effect in the treatment of type 2 diabetes mellitus with high risk of cardiovascular disease.It can effectively improve its blood glucose and blood lipid level,and it is safe to use the drug in the treatment of type II diabetes mellitus with high cardiovascular risk,It is worth popularizing and applying in clinic.